About: Colleoni M

Documentation

scienceplus.abes.fr version Bêta

scienceplus.abes.fr | explorer

À propos de : Colleoni M Goto Sponge NotDistinct Permalink

Attributs	Valeurs
type	Person
name	Colleoni M Colleoni M. Colleoni Marco
personal mailbox	marco.colleoni@ieo.it
familyName	Colleoni
Given name	M M. Marco
is relates of	http://hub.abes.fr/oup/periodical/annonc/2003/volume_14/issue_10/101093annoncmdg411/authorship/1 http://hub.abes.fr/oup/periodical/annonc/2004/volume_15/issue_2/101093annoncmdh054/authorship/1 http://hub.abes.fr/oup/periodical/annonc/2004/volume_15/issue_4/101093annoncmdh146/authorship/6 http://hub.abes.fr/oup/periodical/annonc/2008/volume_19/issue_6/101093annoncmdn005/authorship/25 http://hub.abes.fr/oup/periodical/annonc/2009/volume_20/issue_9/101093annoncmdp033/authorship/11 http://hub.abes.fr/oup/periodical/annonc/1998/volume_9/issue_9/101023a1008273110272/authorship/3 http://hub.abes.fr/oup/periodical/annonc/2005/volume_16/issue_5/101093annoncmdi163/authorship/1 http://hub.abes.fr/oup/periodical/annonc/2009/volume_20/issue_7/101093annoncmdn747/authorship/1 http://hub.abes.fr/oup/periodical/jnci/2008/volume_100/issue_3/101093jncidjm289/authorship/6 http://hub.abes.fr/oup/periodical/annonc/1999/volume_10/issue_8/101023a1008389106575/authorship/3 http://hub.abes.fr/oup/periodical/annonc/2007/volume_18/issue_10/101093annoncmdm268/authorship/1 http://hub.abes.fr/oup/periodical/annonc/2006/volume_17/issue_suppl7/101093annoncmdl943/authorship/3 http://hub.abes.fr/oup/periodical/annonc/2010/volume_21/issue_suppl7/101093annoncmdq281/authorship/1 http://hub.abes.fr/oup/periodical/annonc/2006/volume_17/issue_10/101093annoncmdl145/authorship/1 http://hub.abes.fr/oup/periodical/annonc/2008/volume_19/issue_3/101093annoncmdm509/authorship/1 http://hub.abes.fr/oup/periodical/annonc/2005/volume_16/issue_suppl1/101093annoncmdi816/authorship/2 http://hub.abes.fr/oup/periodical/annonc/2009/volume_20/issue_8/101093annoncmdp024/authorship/1 http://hub.abes.fr/oup/periodical/annonc/1999/volume_10/issue_11/101023a1008356726147/authorship/2 http://hub.abes.fr/oup/periodical/annonc/2000/volume_11/issue_1/101023a1008364801718/authorship/2 http://hub.abes.fr/oup/periodical/annonc/2001/volume_12/issue_5/101023a1011173806900/authorship/3 http://hub.abes.fr/oup/periodical/annonc/2005/volume_16/issue_10/101093annoncmdi304/authorship/2 http://hub.abes.fr/oup/periodical/annonc/2007/volume_18/issue_12/101093annoncmdm201/authorship/7 http://hub.abes.fr/oup/periodical/annonc/2007/volume_18/issue_2/101093annoncmdl354/authorship/12 http://hub.abes.fr/oup/periodical/annonc/2010/volume_21/issue_2/101093annoncmdp317/authorship/8 http://hub.abes.fr/oup/periodical/annonc/2001/volume_12/issue_1/101023a1008334227668/authorship/8 http://hub.abes.fr/oup/periodical/annonc/2010/volume_21/issue_3/101093annoncmdp563/authorship/6 http://hub.abes.fr/oup/periodical/annonc/1998/volume_9/issue_5/101023a1008236502420/authorship/2 http://hub.abes.fr/oup/periodical/annonc/2002/volume_13/issue_2/101093annoncmdf039/authorship/1 http://hub.abes.fr/oup/periodical/annonc/2002/volume_13/issue_6/101093annoncmdf166/authorship/2 http://hub.abes.fr/oup/periodical/annonc/2003/volume_14/issue_8/101093annoncmdg327/authorship/2 http://hub.abes.fr/oup/periodical/annonc/2007/volume_18/issue_2/101093annoncmdl399/authorship/6 http://hub.abes.fr/oup/periodical/annonc/2005/volume_16/issue_4/101093annoncmdi101/authorship/2 http://hub.abes.fr/oup/periodical/annonc/2007/volume_18/issue_suppl6/101093annoncmdm230/authorship/2 http://hub.abes.fr/oup/periodical/annonc/1998/volume_9/issue_10/101023a1008425205941/authorship/1 http://hub.abes.fr/oup/periodical/annonc/2002/volume_13/issue_1/101093annoncmdf013/authorship/1 http://hub.abes.fr/oup/periodical/annonc/2005/volume_17/issue_2/101093annoncmdj066/authorship/1 http://hub.abes.fr/oup/periodical/annonc/2010/volume_21/issue_10/101093annoncmdq072/authorship/15 http://hub.abes.fr/oup/periodical/annonc/2005/volume_16/issue_8/101093annoncmdi255/authorship/1 http://hub.abes.fr/oup/periodical/annonc/2005/volume_17/issue_5/101093annoncmdj087/authorship/1 http://hub.abes.fr/oup/periodical/annonc/2007/volume_18/issue_4/101093annoncmdl492/authorship/7 http://hub.abes.fr/oup/periodical/annonc/2005/volume_16/issue_7/101093annoncmdi213/authorship/5 http://hub.abes.fr/oup/periodical/annonc/2004/volume_15/issue_11/101093annoncmdh434/authorship/1 http://hub.abes.fr/oup/periodical/annonc/2000/volume_11/issue_8/101023a1008334404825/authorship/1
is Author of	Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean) Primary chemotherapy in operable breast cancer with favorable prognostic factors: A pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN) Oesophageal cancer treatment: Studies, strategies and facts The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors Reply to the Letter to the Editor on ‘Cost-opportunity analysis in clinical oncology: from the “wild far-west” to a correct integration of the disciplines, avoiding the “war of the worlds”’, by D. Tassinari et al. (Ann Oncol 2006; 17: 877) Primary systemic therapy on local advance breast cancer, where are we going? Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial Benefits and adverse effects of endocrine therapy Systemic treatments for women with breast cancer: outcome with relation to screening for the disease Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF regimen) Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): Is prophylaxis required? Can tamoxifen relieve motion sickness? Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report Vinorelbine, cisplatin and continuos infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC) Role of fluorodeoxyglucose positron emission tomography in the staging of patients with breast cancer candidated to surgery Bone scan had no role in the staging of 765 consecutive operable T1-2N0-1 breast cancer patients without skeletal symptoms Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies Very young women (<35 years) with operable breast cancer: features of disease at presentation Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: Are all CMFs alike? Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay Management of advanced breast cancer Assessment of response in primary chemotherapy for breast cancer Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer Reply to the article “Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity” by V. R. Rozados et al. (Ann Oncol 2004; 15: 1543-1550): … and in humans? Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials Treatment of advanced breast cancer: the good, the bad and the ugly

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata